Alternatived Products of [ 133970-31-7 ]
Product Details of [ 133970-31-7 ]
CAS No. : | 133970-31-7 |
MDL No. : | MFCD00065664 |
Formula : |
C29H29ClN2O6
|
Boiling Point : |
- |
Linear Structure Formula : | - |
InChI Key : | VUEYAXRHPZGZOL-SANMLTNESA-N |
M.W : | 537.00 g/mol |
Pubchem ID : | 45073227 |
Synonyms : |
|
Safety of [ 133970-31-7 ]
Application In Synthesis of [ 133970-31-7 ]
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
- Downstream synthetic route of [ 133970-31-7 ]
- 1
-
[ 133970-31-7 ]

-
[ 105047-45-8 ]
Yield | Reaction Conditions | Operation in experiment |
83.6% |
With trifluorormethanesulfonic acid; methyl-phenyl-thioether; trifluoroacetic acid at 4℃; for 1h; |
|
- 2
-
Fmoc-Leu-preloaded Wang resin, deprotected
[ No CAS ]

-
[ 35661-40-6 ]

-
[ 86123-10-6 ]

-
[ 103478-58-6 ]

-
Fmoc-Lys(ClZ)-OH
[ No CAS ]

-
NH2-Phe-D-Phe-Lys(2-Cl-Z)-N-Me-Val-Leu-OH
[ No CAS ]
- 3
-
[ 35661-60-0 ]

-
[ 103-40-2 ]

-
[ 71989-33-8 ]

-
[ 116611-64-4 ]

-
Fmoc-Lys(ClZ)-OH
[ No CAS ]

-
BnO-succinyl-His-Ser-Ser-Lys(2-Cl-Z)-Leu-OH
[ No CAS ]
Yield | Reaction Conditions | Operation in experiment |
459 mg |
|
General procedure: All of the peptides were synthesized by Merrifield solid-phase peptide synthesis protocols using a double-coupling protocol on a bubbler peptide synthesizer. The resins for the peptide assembly were 2-methoxy-4-alkoxybenzyl alcohol (SASRIN, 200-400 mesh) resin, purchased from Bachem (Torrance, CA), or 4-hydroxymethylphenoxy (WANG-type HMP) resin, purchased from Advanced Chemtech (Louisville, KY). Nalpha-Fmoc-protected amino acids of the l-configuration and reagents were purchased from Advanced Chemtech. Side-chain protection was Ser(But) and Lys(Cl-Z). The capping group was introduced via monobenzyl succinate or monobenzyl glutarate. C-terminal amino acid was loaded using DMAP/DIC protocol for SASRIN resin, and HOBt/DMAP/DIC protocol for WANG resin, and threefold excess of activated protected amino acid was used for each coupling and recoupling, using NMP as solvent. Following completion of the assembly on the resin support, the N-terminal Fmoc group was removed via the standard 25% piperidine/NMP protocol, followed by washing 5 times with NMP and introduction of N-terminal capping group. Deprotection and removal of the peptide from the resin support were effected using 90% TFA in CH2Cl2 for both SASRIN and WANG resin. The benzyl esters of the capping groups were not affected under these conditions. After removal of solvents under reduced pressure, the peptides were purified by preparative HPLC on a reverse-phase radial compression C18 column (Waters, 15mum, 100A, 5×30cm). A step gradient was generated from 1L each of successively increasing concentration of mobile phase (solvent A, 0.1% TFA/H2O; solvent B, 0.1% TFA/CH3CN). A flow rate of 9mL/min was used to elute the peptide. Detection was performed by monitoring the UV absorbance at 220nm. Homogeneous product fractions (>98% pure) were pooled and freeze-dried. The homogeneity of the peptides was demonstrated by analytical reverse phase HPLC using a C18 column. Identities were confirmed by mass spectral analysis. |
- 4
-
[ 35661-60-0 ]

-
[ 103-40-2 ]

-
[ 71989-33-8 ]

-
[ 133970-31-7 ]

-
[ 1486479-05-3 ]
Yield | Reaction Conditions | Operation in experiment |
538 mg |
Stage #1: Fmoc-Leu-OH With dmap; diisopropyl-carbodiimide In 1-methyl-pyrrolidin-2-one Automated synthesizer;
Stage #2: With piperidine In 1-methyl-pyrrolidin-2-one Automated synthesizer;
Stage #3: succinic acid monobenzyl ester; Fmoc-Ser(tBu)-OH; Fmoc-Lys(ClZ)-OH Further stages; |
6.1.10 General methods for peptide synthesis
General procedure: All of the peptides were synthesized by Merrifield solid-phase peptide synthesis protocols using a double-coupling protocol on a bubbler peptide synthesizer. The resins for the peptide assembly were 2-methoxy-4-alkoxybenzyl alcohol (SASRIN, 200-400 mesh) resin, purchased from Bachem (Torrance, CA), or 4-hydroxymethylphenoxy (WANG-type HMP) resin, purchased from Advanced Chemtech (Louisville, KY). Nα-Fmoc-protected amino acids of the l-configuration and reagents were purchased from Advanced Chemtech. Side-chain protection was Ser(But) and Lys(Cl-Z). The capping group was introduced via monobenzyl succinate or monobenzyl glutarate. C-terminal amino acid was loaded using DMAP/DIC protocol for SASRIN resin, and HOBt/DMAP/DIC protocol for WANG resin, and threefold excess of activated protected amino acid was used for each coupling and recoupling, using NMP as solvent. Following completion of the assembly on the resin support, the N-terminal Fmoc group was removed via the standard 25% piperidine/NMP protocol, followed by washing 5 times with NMP and introduction of N-terminal capping group. Deprotection and removal of the peptide from the resin support were effected using 90% TFA in CH2Cl2 for both SASRIN and WANG resin. The benzyl esters of the capping groups were not affected under these conditions. After removal of solvents under reduced pressure, the peptides were purified by preparative HPLC on a reverse-phase radial compression C18 column (Waters, 15μm, 100Å, 5×30cm). A step gradient was generated from 1L each of successively increasing concentration of mobile phase (solvent A, 0.1% TFA/H2O; solvent B, 0.1% TFA/CH3CN). A flow rate of 9mL/min was used to elute the peptide. Detection was performed by monitoring the UV absorbance at 220nm. Homogeneous product fractions (>98% pure) were pooled and freeze-dried. The homogeneity of the peptides was demonstrated by analytical reverse phase HPLC using a C18 column. Identities were confirmed by mass spectral analysis. |
- 5
-
[ 133970-31-7 ]

-
[ 1204431-11-7 ]
Yield | Reaction Conditions | Operation in experiment |
|
Multi-step reaction with 3 steps
1.1: diisopropyl-carbodiimide; benzotriazol-1-ol / N,N-dimethyl-formamide / 1 h
1.2: 2.5 h / 25 °C
2.1: pyridine hydrochloride
2.2: 24 h
3.1: hydrogen fluoride |
|
Reference:
[1]Enyedi, Kata Nóra; Czajlik, András; Knapp, Krisztina; Láng, András; Majer, Zsuzsa; Lajkó, Eszter; Kohidai, László; Perczel, András; Mezo, Gábor
[Journal of Medicinal Chemistry, 2015, vol. 58, # 4, p. 1806 - 1817]
- 6
-
[ 133970-31-7 ]

-
[ 1675230-39-3 ]
Yield | Reaction Conditions | Operation in experiment |
|
Multi-step reaction with 2 steps
1.1: diisopropyl-carbodiimide; benzotriazol-1-ol / N,N-dimethyl-formamide / 1 h
1.2: 2.5 h / 25 °C
2.1: pyridine hydrochloride
2.2: 24 h |
|
Reference:
[1]Enyedi, Kata Nóra; Czajlik, András; Knapp, Krisztina; Láng, András; Majer, Zsuzsa; Lajkó, Eszter; Kohidai, László; Perczel, András; Mezo, Gábor
[Journal of Medicinal Chemistry, 2015, vol. 58, # 4, p. 1806 - 1817]
- 7
-
[ 133970-31-7 ]

-
[ CAS Unavailable ]
Yield | Reaction Conditions | Operation in experiment |
|
Multi-step reaction with 4 steps
1.1: diisopropyl-carbodiimide; benzotriazol-1-ol / N,N-dimethyl-formamide / 1 h
1.2: 2.5 h / 25 °C
2.1: pyridine hydrochloride
2.2: 24 h
3.1: hydrogen fluoride
4.1: Dulbecco's modified Eagle's medium GlutaMAX-I / 24 h / 37 °C |
|
Reference:
[1]Enyedi, Kata Nóra; Czajlik, András; Knapp, Krisztina; Láng, András; Majer, Zsuzsa; Lajkó, Eszter; Kohidai, László; Perczel, András; Mezo, Gábor
[Journal of Medicinal Chemistry, 2015, vol. 58, # 4, p. 1806 - 1817]
- 8
-
[ 133970-31-7 ]

-
[ CAS Unavailable ]

-
[ CAS Unavailable ]
Yield | Reaction Conditions | Operation in experiment |
|
Multi-step reaction with 4 steps
1.1: diisopropyl-carbodiimide; benzotriazol-1-ol / N,N-dimethyl-formamide / 1 h
1.2: 2.5 h / 25 °C
2.1: pyridine hydrochloride
2.2: 24 h
3.1: hydrogen fluoride
4.1: Dulbecco's modified Eagle's medium GlutaMAX-I / 48 h / 37 °C |
|
Reference:
[1]Enyedi, Kata Nóra; Czajlik, András; Knapp, Krisztina; Láng, András; Majer, Zsuzsa; Lajkó, Eszter; Kohidai, László; Perczel, András; Mezo, Gábor
[Journal of Medicinal Chemistry, 2015, vol. 58, # 4, p. 1806 - 1817]
- 9
-
[ CAS Unavailable ]

-
[ 76-05-1 ]

-
[ 133970-31-7 ]

-
[ 1675230-40-6 ]
Yield | Reaction Conditions | Operation in experiment |
|
Stage #1: C17H30N9O7Pol; Fmoc-Lys(ClZ)-OH With benzotriazol-1-ol; diisopropyl-carbodiimide In N,N-dimethyl-formamide for 1h;
Stage #2: trifluoroacetic acid With chlorotriisopropylsilane In water at 25℃; for 2.5h; |
|
Reference:
[1]Enyedi, Kata Nóra; Czajlik, András; Knapp, Krisztina; Láng, András; Majer, Zsuzsa; Lajkó, Eszter; Kohidai, László; Perczel, András; Mezo, Gábor
[Journal of Medicinal Chemistry, 2015, vol. 58, # 4, p. 1806 - 1817]
- 10
-
2-chlorotrityl chloride polystyrene resin
[ No CAS ]

-
[ 35661-40-6 ]

-
[ 115186-31-7 ]

-
FMoc-L-2,6-dimethyltyrosine
[ No CAS ]

-
Fmoc-Lys(ClZ)-OH
[ No CAS ]

-
C64H73Cl2N6O10Pol
[ No CAS ]